Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells $78,297.48 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the sale, the director now directly owns 7,109,875 shares of the company’s stock, valued at approximately $48,631,545. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64.
• On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.82, for a total value of $78,068.54.
• On Tuesday, July 23rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.48, for a total value of $97,070.56.
• On Tuesday, July 9th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.32, for a total value of $83,792.04.
• On Tuesday, June 25th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total value of $108,860.97.

Recursion Pharmaceuticals Trading Down 2.0 %

NASDAQ RXRX opened at $6.80 on Friday. The stock’s 50 day moving average is $7.18 and its 200 day moving average is $8.41. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.62 billion, a PE ratio of -4.25 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same period in the prior year, the company earned ($0.38) earnings per share. The firm’s quarterly revenue was up 30.9% compared to the same quarter last year. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in RXRX. Victory Capital Management Inc. boosted its holdings in Recursion Pharmaceuticals by 34.1% in the fourth quarter. Victory Capital Management Inc. now owns 20,441 shares of the company’s stock worth $202,000 after acquiring an additional 5,195 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Recursion Pharmaceuticals by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,190,882 shares of the company’s stock worth $11,742,000 after buying an additional 32,916 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Recursion Pharmaceuticals by 152.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,137,110 shares of the company’s stock valued at $21,079,000 after buying an additional 1,291,946 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 5.9% during the fourth quarter. Principal Financial Group Inc. now owns 683,608 shares of the company’s stock valued at $6,740,000 after buying an additional 38,133 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $34,825,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RXRX. Jefferies Financial Group lowered their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.